MAP4K1 and cancer: The HPK1 biopathway has been identified as a promising target for drug development aimed at treating various types of cancers, such as melanoma, lung, breast, and ovarian cancers, and it presents a viable option for developing cancer immunotherapy treatment [7,8,9].